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OBJECTIVE— To compare the use of GHb and fasting plasma glucose (FPG) to define the
metabolic syndrome (MetS).
RESEARCH DESIGN AND METHODS— Data from the U.S. National Health and
Nutrition Examination Survey 1999–2006 were used. MetS was defined using the consensus
criteria in 2009. Raised blood glucose was defined as either FPG 100 mg/dl (5.6 mmol/l) or
GHb 5.7%.
RESULTS— In 2003–2006, there was 91.3% agreement between GHb and FPG when either
was used to define MetS. The agreement was good irrespective of age, sex, race/ethnicity, BMI,
and diabetes status (87.4%). Similar results were found in 1999–2002. Among subjects
without diabetes, only the use of GHb alone, but not FPG, resulted in significant association with
cardiovascular diseases (odds ratio 1.45, P  0.005).
CONCLUSIONS— Using GHb instead of FPG to define MetS is feasible. It also identifies
individuals with increased cardiovascular risk.
Diabetes Care 33:1856–1858, 2010
The metabolic syndrome (MetS) de-scribes the clustering of closely re-lated cardiovascular risk factors (1).
The definition of MetS, proposed in 2001
by the National Cholesterol Education
Program (NCEP) Expert Panel (2), was
later modified in accordance with the re-
vised definition of impaired fasting glu-
cose from the American Diabetes
Association (ADA) in 2004 (1,3). Re-
cently, a unified definition of MetS was
proposed jointly by several organizations
in 2009 (4), while ADA proposed the use
of GHb in the definition of diabetes and
the category of increased diabetes risk
(which also includes impaired fasting glu-
cose and impaired glucose tolerance) in
2010 (5). Therefore, we investigated
whether GHb can be used instead of fast-
ing plasma glucose (FPG) in identifying
individuals with MetS.
RESEARCH DESIGN AND
METHODS— Data from the cross-
sectional U.S. National Health and Nutri-
tion Examination Survey (NHANES)
2003–2006 were used in initial analysis
(6). For confirmation, we used the cross-
sectional data from NHANES 1999 –
2002. All participants gave informed
consent, and the study received approval
from the Centers for Disease Control and
Prevention Institutional Review Board.
MetS was defined using the consen-
sus criteria in 2009 (4). Under this defi-
nition, a person has MetS if he or she
meets three or more of the following cri-
teria: 1) central obesity, defined using
ethnic-specific cut points of waist circum-
ference, 2) triglycerides150 mg/dl (1.7
mmol/l), 3) HDL cholesterol 40 mg/dl
(1.0 mmol/l) in men and50 mg/dl (1.3
mmol/l) in women, 4) blood pressure
130/85 mmHg or on antihypertensive
medication, or 5) raised blood glucose,
defined as FPG100 mg/dl (5.6 mmol/l)
or on antidiabetic medication. For non-
Hispanic whites and blacks, and people of
other races and mixed races, the cut
points for waist circumference were 94
cm in men and 80 cm in women. For
Mexican Americans and other Hispanics,
the cut points were 90 cm in men and
80 cm in women. In a separate analysis,
MetS was defined using the NCEP crite-
ria, which were the same as the consensus
criteria in 2009 (4), except that central
obesity was defined as waist circumfer-
ence 102 cm in men and 88 cm in
women (1,3). The uses of GHb5.7% or
FPG 100 mg/dl in the definition of the
glycemic component of MetS were com-
pared. Agreement between two defini-
tions was defined as the percentage of
participants who were classified the same
under both definitions (7,8).
The laboratory methods have been
described in detail elsewhere (6,8–11).
Data on GHb and FPG were adjusted so
that measurements across survey periods
could be combined (6). History of cardio-
vascular diseases was obtained from
self-reported questionnaires. Statistical
analysis was performed using the com-
plex samples function of SPSS version
15.0 (SPSS, Chicago, IL). Fasting sam-
pling weights were used in all analyses to
adjust for oversampling and nonresponse
bias and to approximate the distribution
to the U.S. population in the year 2000.
RESULTS— After excluding pregnant
women and subjects with missing data in
BMI, GHb, and the five components of
MetS, there were 3,551 and 3,412 partic-
ipants aged 20 years in NHANES
1999 –2002 and 2003–2006, respec-
tively, who had fasted for 8–24 h.
As shown in Table 1, in NHANES
2003–2006, the use of GHb alone re-
sulted in a lower percentage of people
meeting the glycemic criteria of MetS
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compared with the use of FPG alone, with
74.9% agreement between these two def-
initions. The use of GHb alone also re-
sulted in a lower prevalence of MetS
compared with the use of FPG alone (Ta-
ble 1). The use of both GHb and FPG
resulted in an insignificant increase in the
prevalence compared with the use of FPG
alone (41.1 vs. 38.8%, P 0.200). There
was 91.3% agreement between the use of
GHb alone and the use of FPG alone. The
agreement was good irrespective of age,
sex, race/ethnicity, and BMI. The same
trends were found in NHANES 1999–
2002 or when the NCEP definition was
used (see supplementary Tables A1 and
A2, available in an online appendix at
http://care.diabetesjournals.org/cgi/
content/full/dc09-0190/DC1).
Because there is controversy whether
the diagnosis of MetS conveys additional
meaning in subjects with diabetes who
should already be aggressively treated due
to high cardiovascular risk, a subgroup
without diabetes (non-DM) was also ex-
amined. Similar to the overall cohort, in
the non-DM group, the use of GHb alone
resulted in lower prevalence of MetS com-
pared with FPG alone, with 90.6% agree-
ment (Table 1). Importantly, in this
non-DM subgroup, only the use of GHb
alone, but not FPG, resulted in significant
association with cardiovascular diseases
(odds ratio 1.45, P  0.005) when the
consensus criteria in 2009 was used to
define MetS (supplementary Table A3).
CONCLUSIONS— The controversy
regarding the definition of MetS has been
addressed recently in a joint scientific
statement (4). GHb reflects the average
blood glucose level over several months,
and its measurement does not require a
fasting blood sample. In this study, we
demonstrated that there was good agree-
ment between GHb and FPG in identify-
ing individuals with MetS, despite only a
moderate agreement (75%) between
GHb and FPG in defining raised blood
glucose. The components of MetS are in-
ter-correlated; therefore, a certain degree
of inaccuracy or fluctuation in one com-
ponent is tolerated and does not result in
misclassification. The agreement between
GHb and FPG in the definition of MetS is
good in different subgroups. We can
therefore confidently conclude that using
GHb instead of FPG to define MetS is fea-
sible. This is true at least for Americans,
based on the most up-to-date data on a
nationally representative sample of Amer-
icans, and was confirmed using historical
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data. It remains to be seen if our conclu-
sions are also applicable to Asians, among
whom the prevalence of raised blood glu-
cose is likely to be different.
The current cut point of GHb identi-
fies a slightly smaller group of people as
having MetS. However, it also identifies
subjects at high risk for cardiovascular
diseases, even in those without diabetes,
when the consensus criteria in 2009 are
used to define MetS. Whether GHb re-
sults in better risk stratification needs to
be investigated in large prospective
studies.
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